0001209191-22-020949.txt : 20220324
0001209191-22-020949.hdr.sgml : 20220324
20220324173652
ACCESSION NUMBER: 0001209191-22-020949
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220323
FILED AS OF DATE: 20220324
DATE AS OF CHANGE: 20220324
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: THURMAN RANDY H
CENTRAL INDEX KEY: 0001204059
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 22767650
MAIL ADDRESS:
STREET 1: 222 MERCHANDISE MART PLAZA
STREET 2: SUITE 2024
CITY: CHICAGO
STATE: IL
ZIP: 60654
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-23
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001204059
THURMAN RANDY H
C/O OUTLOOK THERAPEUTICS, INC.
485 ROUTE 1 SOUTH, BUILDING F, SUITE 320
ISELIN
NJ
08830
1
0
0
0
Stock Option (Right to Buy)
1.92
2022-03-23
4
A
0
81878
0.00
A
2032-03-23
Common Stock
81878
81878
D
The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
/s/ Lawrence Kenyon, Attorney-in-Fact
2022-03-24